Evidence map›Paper›PMID 24335969›Full record

Trial reportJournal of the American Society of Nephrology : JASN2014

Long-term effects of spironolactone in peritoneal dialysis patients.

Yasuhiko Ito, Masashi Mizuno, Yasuhiro Suzuki, Hirofumi Tamai, Takeyuki Hiramatsu, Hiroshige Ohashi, Isao Ito, Hirotake Kasuga, Masanobu Horie, Shoichi Maruyama and 4 more

Open access · greenAbstract readMulticenter StudyRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Journal of the American Society of Nephrology : JASN, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 39 papers, 9 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
39citing papers in PubMed, 9 pooled it
4.5field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

39 citing papers in PubMed, 9 syntheses or guidelines pooled it, 91 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Guideline
  9. Pooled it
  10. Trial
  11. Trial
  12. Trial
  13. Trial
  14. Trial
  15. The Safety of Eplerenone in Hemodialysis Patients: A Noninferiority Randomized Controlled Trial.Clinical journal of the American Society of Nephrology : CJASN · 2015
    Trial
  16. Mineralocorticoid Receptor Antagonists in Dialysis.American journal of nephrology · 2026
    Review
  17. Review
  18. Review
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 9 institutions in 1 country.

Yasuhiko ItoNephrology and Renal Replacement Therapy, Nagoya University, Nagoya, Japan; yasuito@med.nagoya-u.ac.jp.
Masashi MizunoNephrology and Renal Replacement Therapy, Nagoya University, Nagoya, Japan;
Yasuhiro SuzukiNephrology and Renal Replacement Therapy, Nagoya University, Nagoya, Japan;
Hirofumi TamaiAnjyo Kosei Hospital, Japan;
Takeyuki HiramatsuKonan Kosei Hospital, Japan;
Hiroshige OhashiGifu Prefectural General Medical Center, Japan;
Isao ItoYokkaichi Municipal Hospital, Japan;
Hirotake KasugaNagoya Kyoritsu Hospital, Japan;
Masanobu HorieDaiyukai Daiichi Hospital, Japan;
Shoichi MaruyamaNephrology and Renal Replacement Therapy, Nagoya University, Nagoya, Japan;
Yukio YuzawaFujita Health University, Toyoake, Japan; and.
Tatsuaki MatsubaraAichi Gakuin University, Nagoya, Japan.
Seiichi MatsuoNephrology and Renal Replacement Therapy, Nagoya University, Nagoya, Japan;
Nagoya Spiro Study Group
Nagoya University · JPAichi Gakuin University · JPAnjo Kosei Hospital · JPDaiyūkaidaiichi Hospital · JPFujita Health University · JPGifu Prefectural General Medical Center · JPHiroshima Kyoritsu Hospital · JPKonan Kosei Hospital · JPYokkaichi Municipal Hospital · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

ESRD treated with dialysis is associated with increased left ventricular hypertrophy, which, in turn, is related to high mortality. Mineralocorticoid receptor antagonists improve survival in patients with chronic heart failure; however, the effects in patients undergoing dialysis remain uncertain. We conducted a multicenter, open-label, prospective, randomized trial with 158 patients receiving angiotensin-converting enzyme inhibitor or angiotensin type 1 receptor antagonist and undergoing peritoneal dialysis with and without (control group) spironolactone for 2 years. As a primary endpoint, rate of change in left ventricular mass index assessed by echocardiography improved significantly at 6 (P=0.03), 18 (P=0.004), and 24 (P=0.01) months in patients taking spironolactone compared with the control group. Rate of change in left ventricular ejection fraction improved significantly at 24 weeks with spironolactone compared with nontreatment (P=0.02). The benefits of spironolactone were clear in patients with reduced residual renal function. As secondary endpoints, renal Kt/V and dialysate-to-plasma creatinine ratio did not differ significantly between groups during the observation period. No serious adverse effects, such as hyperkalemia, occurred. In this trial, spironolactone prevented cardiac hypertrophy and decreases in left ventricular ejection fraction in patients undergoing peritoneal dialysis, without significant adverse effects. Further studies, including those to determine relative effectiveness in women and men and to evaluate additional secondary endpoints, should confirm these data in a larger cohort.

Indexed as

AdultAgedAngiotensin-Converting Enzyme InhibitorsAngiotensin II Type 1 Receptor BlockersDrug Therapy, CombinationFemaleHumansHypertrophy, Left VentricularKidney Failure, ChronicMaleMiddle AgedMineralocorticoid Receptor AntagonistsPeritoneal DialysisProspective StudiesSpironolactoneStroke VolumeAngiotensin-Converting Enzyme InhibitorsAngiotensin II Type 1 Receptor BlockersMineralocorticoid Receptor AntagonistsSpironolactone

Identifiers

PMID24335969
PMCPMC4005296
OpenAlexW2131212340

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.